← Back to Search

Procedure

Fat Tissue Injection vs Corticosteroid Injection for Shoulder Pain in Spinal Cord Injury (MFAT-SCI Trial)

Phase 2
Recruiting
Research Sponsored by Kessler Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men and women, 18 to 70 years of age, inclusive
Currently has chronic shoulder pain due to rotator cuff disease in spite of at least 6 months of conservative treatment
Must not have
Report prior MFAT treatment
Have a contra-indication to the procedure, such as infection, coagulopathy, or currently taking anti-coagulant
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Summary

This trial is studying a new treatment for shoulder pain in people with chronic spinal cord injury. The new treatment is an injection of fat tissue, and the study will compare it to the standard-of-care corticosteroid injection.

Who is the study for?
This trial is for adults aged 18-70 with chronic shoulder pain due to rotator cuff disease, who have had a spinal cord injury between C6 and L5 at least one year ago. Participants must be wheelchair users (over 40 hours/week) and have not found relief from pain after six months of conservative treatment. They cannot join if they have systemic disorders like diabetes or rheumatoid arthritis, previous adipose tissue injections, contraindications like infection or coagulopathy, are pregnant, or recently had corticosteroid injections.Check my eligibility
What is being tested?
The study compares the effectiveness of Lipogems®, an injection of micro-fragmented adipose tissue guided by ultrasound, against dexamethasone (a corticosteroid) for relieving chronic shoulder pain in wheelchair users with spinal cord injuries. The goal is to see if Lipogems® can provide better long-term relief without the potential tendon damage associated with repeated steroid use.See study design
What are the potential side effects?
Potential side effects may include reactions at the injection site such as pain or swelling, risk of infection, and possible allergic reactions to materials used during the procedure. Long-term side effects are unknown but could involve changes in fat distribution around the injected area.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 70 years old.
Select...
I have had shoulder pain for over 6 months despite treatment.
Select...
I have shoulder pain confirmed by an ultrasound to be due to rotator cuff issues.
Select...
My shoulder pain has been at least a 4 out of 10 in the past week.
Select...
I use a wheelchair for most of my daily activities but can exercise.
Select...
My shoulder pain has been at least a 4 out of 10 in the past week.
Select...
I have had a spinal cord injury between my neck and lower back over a year ago.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have received MFAT treatment before.
Select...
I cannot undergo the procedure due to an infection, bleeding disorder, or because I'm on blood thinners.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Numerical Rating Scale
Secondary outcome measures
Patient Global Impression of Change
Shoulder
Quantitative Ultrasound of the Supraspinatus Tendon
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Micro-Fragmented Adipose TissueExperimental Treatment1 Intervention
Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear, subacromial bursa, glenohumeral joint, acromioclavicular joint) under ultrasound guidance using an 18 gauge x 3.5 inch needle.
Group II: CorticosteroidActive Control1 Intervention
Participants will receive a corticosteroid injection (BMS, Kenacort-A 40 mg [triamcinolone acetonide]) into the subacromial space under direct ultrasound guidance by means of a 5-mL syringe with a 22-guage needle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lipogems
2017
Completed Phase 2
~150

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for shoulder pain include physical therapy, corticosteroid injections, and autologous adipose tissue injections. Physical therapy aims to strengthen muscles and improve joint mobility, thereby reducing pain and preventing further injury. Corticosteroid injections provide temporary relief by reducing inflammation but may accelerate tendon degeneration over time. Autologous adipose tissue injections, such as Lipogems®, offer cushioning and filling of structural defects in the shoulder. These injections are rich in bioactive elements and regenerative perivascular cells (pericytes), which promote tissue repair and reduce inflammation. This matters for shoulder pain patients as it provides a regenerative treatment option that not only alleviates pain but also supports tissue healing and long-term joint health.
Injectable, porous, biohybrid hydrogels incorporating decellularized tissue components for soft tissue applications.The role of bone marrow mesenchymal stromal cell derivatives in skin wound healing in diabetic mice.Effect of P144® (Anti-TGF-β) in an "In Vivo" Human Hypertrophic Scar Model in Nude Mice.

Find a Location

Who is running the clinical trial?

Kessler FoundationLead Sponsor
175 Previous Clinical Trials
10,734 Total Patients Enrolled
2 Trials studying Shoulder Pain
16 Patients Enrolled for Shoulder Pain

Media Library

Lipogems (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04136743 — Phase 2
Shoulder Pain Research Study Groups: Corticosteroid, Micro-Fragmented Adipose Tissue
Shoulder Pain Clinical Trial 2023: Lipogems Highlights & Side Effects. Trial Name: NCT04136743 — Phase 2
Lipogems (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04136743 — Phase 2
Shoulder Pain Patient Testimony for trial: Trial Name: NCT04136743 — Phase 2
~4 spots leftby Jul 2025